Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
Isotretinoin
Roche Products (Ireland) Ltd
D10BA; D10BA01
Isotretinoin
10 milligram(s)
Capsule, soft
Product subject to prescription which may not be renewed (A)
Retinoids for treatment of acne; isotretinoin
Marketed
2006-11-20
1 IE-PIL-RoAccutane_soft capsules_10-20 mg _22 Jan 2024_Clean PACKAGE LEAFLET: INFORMATION FOR THE USER ROACCUTANE 10 MG AND 20 MG SOFT CAPSULES isotretinoin WARNING CAN SERIOUSLY HARM AN UNBORN BABY Women must use effective contraception Do not use if you are pregnant or think you may be pregnant READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep the leaflet. You may need to read it again. • If you have more questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Roaccutane is and what it is used for 2. What you need to know before you take Roaccutane 3. How to take Roaccutane 4. Possible side effects 5. How to store Roaccutane 6. Contents of the pack and other information 1. WHAT ROACCUTANE IS AND WHAT IT IS USED FOR Roaccutane contains _isotretinoin_ – a substance related to vitamin A, and one of a group of medicines called _ retinoids_ (for treatment of acne) _. _ _ _ ROACCUTANE IS USED TO TREAT SEVERE FORMS OF ACNE (such as _nodular _ or _conglobate_ acne, or acne that is at risk of causing permanent scarring) in adults and adolescents. You will use Roaccutane when your acne has not got better with anti-acne treatments, including antibiotics and skin treatments. Roaccutane should not be used to treat prepubertal acne and not in children aged less than 12 years of age. ROACCUTANE TREATMENT MUST BE SUPERVISED BY A DERMATOLOGIST (a doctor specialised in the treatment of skin problems). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ROACCUTANE DO NOT TAKE ROACCUTANE: • If you are pregnant or breast-feeding 2 IE-PIL-RoAccutane_soft capsules_10-20 mg _22 Jan 2024_Clean • If there is any chance you could become pregn Lesen Sie das vollständige Dokument
Health Products Regulatory Authority 11 March 2024 CRN00F2RV Page 1 of 12 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Roaccutane 10 mg soft capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each soft capsule contains 10 mg of isotretinoin. Excipients with known effect: Contains soya-bean oil (refined, hydrogenated and partially hydrogenated) and sorbitol. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsules, soft 10 mg capsules: Oval, opaque, brown-red capsules imprinted with ROA 10 in black ink. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Severe forms of acne (such as nodular or conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of standard therapy with systemic anti-bacterials and topical therapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Isotretinoin should only be prescribed by or under the supervision of physicians with expertise in the use of systemic retinoids for the treatment of severe acne and a full understanding of the risks of isotretinoin therapy and monitoring requirements. The capsules should be taken with food once or twice daily. _Paediatric Population_ Roaccutane should not be used for the treatment of prepubertal acne and is not recommended in children less than 12 years of age due to a lack of data on efficacy and safety. _Adults including adolescents and the elderly:_ Isotretinoin therapy should be started at a dose of 0.5 mg/kg daily. The therapeutic response to isotretinoin and some of the adverse effects are dose-related and vary between patients. This necessitates individual dosage adjustment during therapy. For most patients, the dose ranges from 0.5‑1.0 mg/kg per day. Long-term remission and relapse rates are more closely related to the total dose administered than to either duration of treatment or daily dose. It has been shown that no substantial additional benefit is to be expected beyond a cumulative treatment dose of 120‑150 mg/kg. The duration of treatment will depend on the i Lesen Sie das vollständige Dokument